MRM. Masudur Rahman

M. Masudur Rahman

*This is an algorithmically generated author record based on publicly available information.

M. Masudur Rahman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammad Jahan Shams

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    2 shared publications
  • Shourov Biswas

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD

    2 shared publications
  • Ekram B. Faruq

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD

    1 shared publication
  • Mostafa S. Haque

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD

    1 shared publication
  • Mostafa Sanaul Haque

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    1 shared publication
  • Sarwar Alam

    Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD

    1 shared publication

Latest Publications

  • Open Access

    Weekly Versus Three-Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2 Negative, Stage III Breast Cancer: A Comparison of Treatment Responses

    by Shourov Biswas, Masudur Rahman, Sarwar Alam, Mostafa S. Haque, Ekram B. Faruq, Mohammad J. Shams, Soma Banerjee

    Background and aim: Neoadjuvant chemotherapy with doxorubicin (A) and cyclophosphamide (C) followed by taxane (T) (AC followed by T) is one of the standard regimens in locoregionally advanced breast cancer. Paclitaxel, a taxane, can be given either in a three-weekly or a weekly schedule. The aim of this study was to compare the efficacy in terms of the clinical and pathological response of three-weekly paclitaxel with weekly paclitaxel in the treatment of human epidermal growth factor receptor 2 (HER2)-negative, stage III breast cancer. Materials and methods: A quasi-experimental study was conducted from April 2022 to October 2023 in two centers in Dhaka, Bangladesh. Sixty-six patients were enrolled and divided equally into two arms. Arm-A patients received four cycles of AC followed by paclitaxel (175 mg/m2) three-weekly for four cycles. Patients in Arm-B received four cycles of AC followed by paclitaxel (80 mg/m2) weekly for 12 weeks. Patients were evaluated before, during, and after the completion of the chemotherapy to assess clinical outcomes and were assessed for the pathological response after surgical management. Observations and results: Pathological complete response (pCR) was achieved in 15 (25%) patients. Four patients (13.33%) in Arm A and 11 patients (36.66%) in Arm B had pCR. The difference was statistically significant (p 0.037). The p-value was 0.219 for response at the primary site and 0.13 for response in axillary disease. In both arms, patients with triple-negative receptor status had increased pCR (22.22% or two patients out of nine in Arm A, and 85.71% or six patients out of seven in Arm B) in comparison to hormone receptor (estrogen receptor (ER) and/or progesterone receptor (PR)) positive tumors (9.52% or two patients out of 21 in Arm A, and 21.74% or five patients out of 23 in Arm B). However, these differences were not significant. Conclusion: After three-weekly administrations of four cycles of AC, the weekly administration of paclitaxel was found to be more effective in comparison to three-weekly administration of paclitaxel.


  • Open Access

    Clinico-pathological profile of breast cancer patients in a radiation therapy centre

    by M. Masudur Rahman, Mohammad Jahan Shams, Mostafa Sanaul Haque, Shourov Biswas

    Background: The aim of the study was to evaluate the clinico-pathological characteristics of patients with breast cancer at the Radiation Center of Bangabandhu Sheikh Mujib Medical University (BSMMU), a tertiary‑care cancer center in Dhaka, Bangladesh. Methods: This descriptive study was conducted from March 2021 to February 2022 where patients receiving radiotherapy for breast cancer were included. Data were collected from face-to-face interviews with patients and from their investigation reports. Data regarding age, presenting symptoms, histological type, tumor size, involvement of regional nodes, hormonal receptor status, and human epidermal growth factor receptor 2 (HER2) amplification were recorded and then analyzed. Results: The mean age of the patients was 52.53 years. Most of the patients (93%) were multiparous and 62.24% were postmenopausal. The most common symptom was breast lump (91.6%). Infiltrating ductal carcinoma and lobular carcinoma were seen in 136 (95.1%) and 7 (4.9%) cases respectively. The TNM stage distribution was stage I, 6 (4.2%); stage II, 52 (36.36%); stage III, 76 (53.15%); and stage IV, 9 (6.29%). Locally advanced breast cancer constituted 42.66% of the cases. Among the patients 90 (62.94%) patients were ER/PR positive and 42 (29.37%) patients were HER2 positive. Triple negative breast cancer (TNBC) constituted 25.17% (36) of the study population. All receptors were positive in 25 patients (17.48%). Conclusions: Majority of our patients receiving breast radiotherapy at our center are middle aged and have advanced disease. TNBC and HER2 positive breast cancer are more common in our population.